A resTORbio respiratory drug has failed a late-stage test, and the company is stopping further development of the compound for lung infections in elderly patients.
In the first of two Phase 3 studies, ResTORbio on Friday released preliminary data showing that its drug, RTB101, did not beat a placebo. Though the Boston-based company won’t proceed with the second Phase 3 study, it says it remains committed to developing the pill for other diseases of aging, including Parkinson’s.
Shares of resTORbio (NASDAQ: TORC) plunged more than 87 percent following the news.
ResTORbio is developing a class of drugs that block an… Read more »
UNDERWRITERS AND PARTNERS
